论文部分内容阅读
目的探讨贝伐珠单抗联合阿帕替尼治疗结直肠癌的疗效。方法 60例结直肠癌患者作为研究对象,随机分为试验组和对照组,每组30例。对照组给予阿帕替尼单药治疗,试验组给予贝伐珠单抗联合阿帕替尼治疗。比较两组患者临床疗效、不良反应发生情况、无进展生存期、总生存期和生存质量评分情况。结果试验组总有效率为93.33%,明显高于对照组的76.67%,差异具有统计学意义(P<0.05)。治疗后,试验组患者无进展生存期、总生存期和生存质量评分均明显高于对照组,差异具有统计学意义(P<0.05)。试验组患者不良反应总发生率为13.33%,低于对照组的43.33%,差异具有统计学意义(P<0.05);试验组患者注射局部灶红肿和肝功能异常发生率均明显低于对照组,差异具有统计学意义(P<0.05);两组患者皮疹、中性粒细胞减少和呼吸道感染发生率比较差异无统计学意义(P>0.05)。结论贝伐珠单抗联合阿帕替尼治疗结直肠癌临床疗效显著,且不良反应较轻,值得临床推广。
Objective To investigate the curative effect of bevacizumab combined with apatinib on colorectal cancer. Methods Sixty patients with colorectal cancer were randomly divided into experimental group and control group, with 30 cases in each group. The control group was treated with apatinib monotherapy, and the experimental group was given bevacizumab plus apatinib. Clinical efficacy, adverse reactions, progression-free survival, overall survival and quality of life scores were compared between the two groups. Results The total effective rate of the experimental group was 93.33%, which was significantly higher than that of the control group (76.67%), the difference was statistically significant (P <0.05). After treatment, the progression-free survival, overall survival and quality of life in the test group were significantly higher than the control group, the difference was statistically significant (P <0.05). The total incidence of adverse reactions in the experimental group was 13.33%, which was lower than that in the control group (43.33%), the difference was statistically significant (P <0.05). The incidence of local focal redness and liver dysfunction in the experimental group was significantly lower than that in the control group (P <0.05). There was no significant difference in incidence of rash, neutropenia and respiratory infection between the two groups (P> 0.05). Conclusion Bevacizumab combined with apatinib in the treatment of colorectal cancer has significant clinical efficacy, and mild adverse reactions, it is worth clinical promotion.